Leading PRA’s Center for Vaccine Research, Ms Burton gained her knowledge of vaccine studies with 20+ years of experience in the clinical research industry, including 16 years in project management. Before joining PRA, Ms Burton managed vaccine studies for 3 of the top global vaccine companies. Her vaccine clinical trial experience includes managing Phase I-IV studies in Zika, hepatitis B virus (HBV), influenza, herpes zoster, Lyme disease, polio, chikungunya, and infant combinations vaccines including a hexavalent vaccine. She has managed vaccine studies in the commercial and government environments. Ms. Burton’s global trial experience includes North and South America, Asia Pacific, and Europe. She acquired firsthand knowledge of Europe’s clinical trial practices during a 3-year tenure conducting vaccine trials in the UK. In addition, Lynlee continues to serve as visiting faculty at the University of Siena, teaching the Vaccines Clinical Operations Module for their Masters in Vaccinology and Drug Development program.
Since January 2020, Ms. Burton has been working closely with both clients with COVID-19 vaccines and treatments, ensuring trials are executed as quickly as possible in the race for both a COVID-19 cure and vaccine.
With industry awards for excellence in clinical research and a depth of knowledge of adult and pediatric vaccine trials, Ms. Burton is a vital asset to PRA’s vaccine portfolio.